- Home
- SLN vs NXXT Comparison
SLN vs NXXT Comparison
Compare SLN & NXXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- NXXT
- Stock Information
- Founded
- SLN 1994
- NXXT 2019
- Country
- SLN United Kingdom
- NXXT United States
- Employees
- SLN N/A
- NXXT N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- NXXT
- Sector
- SLN Health Care
- NXXT
- Exchange
- SLN Nasdaq
- NXXT NYSE
- Market Cap
- SLN 273.9M
- NXXT 326.6M
- IPO Year
- SLN N/A
- NXXT N/A
- Fundamental
- Price
- SLN $6.47
- NXXT $2.11
- Analyst Decision
- SLN Buy
- NXXT Strong Buy
- Analyst Count
- SLN 5
- NXXT 1
- Target Price
- SLN $32.60
- NXXT $6.00
- AVG Volume (30 Days)
- SLN 107.6K
- NXXT 224.3K
- Earning Date
- SLN 08-14-2025
- NXXT 08-14-2025
- Dividend Yield
- SLN N/A
- NXXT N/A
- EPS Growth
- SLN N/A
- NXXT N/A
- EPS
- SLN N/A
- NXXT N/A
- Revenue
- SLN $27,701,000.00
- NXXT $37,445,833.00
- Revenue This Year
- SLN N/A
- NXXT N/A
- Revenue Next Year
- SLN N/A
- NXXT N/A
- P/E Ratio
- SLN N/A
- NXXT N/A
- Revenue Growth
- SLN N/A
- NXXT 52.33
- 52 Week Low
- SLN $1.97
- NXXT $2.06
- 52 Week High
- SLN $22.47
- NXXT $6.85
- Technical
- Relative Strength Index (RSI)
- SLN 64.49
- NXXT N/A
- Support Level
- SLN $5.33
- NXXT N/A
- Resistance Level
- SLN $6.55
- NXXT N/A
- Average True Range (ATR)
- SLN 0.44
- NXXT 0.00
- MACD
- SLN 0.02
- NXXT 0.00
- Stochastic Oscillator
- SLN 89.34
- NXXT 0.00
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About NXXT NEXTNRG INC
NextNRG Inc is engaged in developing an integrated ecosystem that combines solar energy generation, battery storage, smart microgrids, wireless electric vehicle (EV) charging, and on-demand fuel delivery. The company is also focused on combining renewable energy innovation with mobile fueling expertise to build a sustainable energy ecosystem that bridges traditional fuel needs with AI-powered clean energy solutions.